Hydrochlorothiazide/Olmesartan Medoxomil

氢氯噻嗪/奥美沙坦酯

Report date: 2023/03/03 20:00:36

Base Information

Drug NameHydrochlorothiazide/Olmesartan Medoxomil
Drug Alias Nameolmesartan medoxomil and hydrochlorothiazide奥美沙坦酯/氢氯噻嗪hydrochlorothiazide and olmesartan medoxomilolmesartan / hydrochlorothiazideolmesartan and hydrochlorothiazide +[8] 
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsThiazide-sensitive sodium-chloride cotransporter inhibitors
TargetsThiazide-sensitive sodium-chloride cotransporterAngiotensin II Receptor Type 1
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited States
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[13] 
CombinationsYes HydrochlorothiazideOlmesartan Medoxomil
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDaiichi Sankyo Europe Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesCosette Pharmaceuticals IncDaiichi Sankyo Pharmaceutical(Shanghai) Co Ltd
Inactive CompaniesDaiichi Sankyo Europe GmbhEmsDaiichi Sankyo Co Ltd
Active IndicationsHypertension
Inactive IndicationsEssential Hypertension

Other Information

ATC CodeC09DA08
Related LinksKEGG